AMD's stock fell sharply post-earnings despite beating Q4 estimates, as its Q1 guidance failed to meet lofty market expectations. The sell-off highlights the punishing standards for AI-focused tech giants and raises questions about stretched valuations across the sector.
While Novo Nordisk pioneered the blockbuster GLP-1 market with Ozempic, Eli Lilly's latest earnings reveal a company pulling ahead in the battle for long-term dominance, fueled by soaring demand for Mounjaro and Zepbound.
Beeline Holdings (BLNE) has secured a pivotal integration deal, embedding its BLINKQC quality control tool directly into the dominant Encompass loan origination ecosystem. The move promises to deliver automated compliance checks to thousands of U.S. lenders within the next quarter.
DA Davidson has lowered its price target on Palantir Technologies (PLTR) from $215 to $180, maintaining a Neutral rating. The firm acknowledges Palantir's strong AI-driven growth but warns its valuation has reached unprecedented levels following a post-earnings surge.
Buzz Bomb Caffeine Company, a subsidiary of Aspire Biopharma (ASBP), has secured a strategic partnership with Blue Shark Beverages to manage and distribute its innovative sublingual caffeine product across Southern California, beginning with a Coachella Valley launch.
Analysts at Northland Capital have downgraded Graham Corporation (NYSE: GHM), citing a stock price nearing full valuation and management's guidance for a significant slowdown in orders by 2026. The move comes just after Graham's strategic $35 million acquisition of mixing technology pioneer FlackTek.
Once a Wall Street darling, The Trade Desk (TTD) has seen its shares collapse by over two-thirds. As the adtech pioneer battles fierce competition and internal turmoil, investors are left weighing its deep value against its uncertain future.
Private payrolls expanded at a far slower pace than anticipated last month, according to ADP data, signaling potential cooling in the labor market as hiring momentum weakens across key industries.
Joe Vitiritto, former PAM Transport CEO, has been appointed President of Knight Transportation, tasked with steering the unit through a prolonged freight downturn and driving profitable growth.
For retirees with substantial 401(k) savings, converting to a Roth IRA offers a path to avoid Required Minimum Distributions (RMDs). But as one 62-year-old with $1.6 million contemplates a $160k annual conversion, experts warn the hefty upfront tax bill could negate the long-term benefits for many.
McDonald's USA has unveiled a series of executive moves, naming Loek Beckers as its new Chief Financial Officer and promoting Luis Quintiliano to U.S. National Field President, as veteran Myra Doria prepares for retirement.
Goldman Sachs' latest Conviction List highlights five dividend-paying stocks with significant projected gains, offering investors a blend of income and growth in a volatile market.
The private sector added a mere 22,000 jobs to start 2026, signaling a persistent slowdown and raising concerns about broader economic resilience as key sectors continue to shed positions.
Orion Energy Systems secures a major contract to deploy 105 fast-charging stations for the Boston Public Schools' bus fleet, marking a significant step in the district's green transition.
A recent 18% monthly surge offers little solace to Franklin Covey investors, as the stock remains down 60% over a three-year horizon, underperforming the broader market and raising questions about the company's turnaround prospects.
Biopharmaceutical firm Ardelyx has been granted a crucial U.S. patent covering the oral formulation of its drug tenapanor, solidifying protection for its commercial products Ibsrela and Xphozah until late 2042 and bolstering its competitive position in the chronic kidney disease treatment landscape.
In a move to diversify critical mineral sources, REalloys and Kazakhstan's AltynGroup have inked preliminary agreements to develop rare earth feedstock from Kazakh deposits for processing in the U.S., challenging China's dominance in the sector.
Biopharma firm Oragenics has enlisted Duck Flats Pharma as its regulatory strategy partner, aiming to synchronize its Australian Phase 2a trial for an intranasal concussion therapy with U.S. FDA requirements for future clinical development.
Fox Corporation reported a mixed second quarter, with overall profits declining despite revenue growth driven by its streaming service Tubi, cable networks, and sports pricing. The company faces headwinds from lower political ad revenue and TV ratings, even as it positions its live news and sports offerings for future election cycles.
Polaryx Therapeutics is set to present new late-breaking data for its investigational therapy PLX-200 at the 2026 WORLDSymposium, bolstering confidence in the upcoming launch of its Phase 2 Soteria trial targeting multiple rare neurodegenerative disorders.
